Last updated on June 2019

Safety of Dabigatran Etexilate in Blood Clot Prevention in Children

Brief description of study

This open-label, single arm prospective cohort study will assess the safety of dabigatran etexilate in secondary prevention of venous thromboembolism in paediatric patients. Children from 0 to less than 18 years of age will be eligible to participate.

Clinical Study Identifier: NCT02197416

Find a site near you

Start Over

HUS, Uusi lastensairaala

Helsinki, Finland
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.